Comparison of Efficacy and Specificity in Cancer-Targeting Prodrug Conjugates

    May 2022 in “ ˜The œFASEB journal ”
    Lillian R. Riederer, Matthew Hammers
    Studysummary This article discusses the development of targeted prodrug conjugates aimed at selectively attacking cancer cells while avoiding healthy ones, but reports no experimental results yet.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on faseb.onlinelibrary.wiley.com →
    Discuss this study in the Community →